Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

9480	Companies
185559	Keywords
117951	Articles
99390	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 04/02/2024 at 14:35, 1 year 8 months ago

Jaguar Health, Inc. Announces Appointment of European Pharmaceutical Industry Veteran as President of Jaguar International

Pharmaceutical Industry Crofelemer Jaguar Health Massimo Radaelli Commercial Expansion
PRESS RELEASE

published on 04/02/2024 at 14:30, 1 year 8 months ago

Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Dr. Massimo Radaelli appointed as President of Jaguar International to expand commercial footprint globally with recent out-license agreement. Key pharmaceutical industry leader with vast experience and expertise

Pharmaceutical Industry Jaguar Health International Expansion Massimo Radaelli Out-license Agreement
BRIEF

published on 04/01/2024 at 14:05, 1 year 8 months ago

Jaguar Health Reports Financial Downturn in 2023 Results

Financial Results Revenue Decline Jaguar Health Mytesi Phase 3 Trial
PRESS RELEASE

published on 04/01/2024 at 14:00, 1 year 8 months ago

Jaguar Health Reports 2023 Financial Results
Jaguar Health, Inc. reports an 18% decrease in net revenue for 2023 compared to 2022. Phase 3 OnTarget trial details and upcoming investor webcast disclosed

Financial Results Investor Webcast Jaguar Health Inc. Net Revenue Phase 3 OnTarget Trial
BRIEF

published on 03/27/2024 at 13:35, 1 year 8 months ago

Jaguar Health, Inc. Schedules Investor Webcast for Q4 2023 Financial Review and Updates

Pharmaceuticals Investor Webcast Jaguar Health Financials Corporate Update
PRESS RELEASE

published on 03/27/2024 at 13:30, 1 year 8 months ago

Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) will conduct an investor webcast on April 1, 2024, at 8:30 a.m. EST to review fourth-quarter financials and corporate updates. Company plans to file its Earnings Report on Form 10-K for year ended December 31, 2023

Earnings Report Investor Webcast Jaguar Health Financials Form 10-K
BRIEF

published on 03/20/2024 at 13:35, 1 year 8 months ago

Jaguar Health, Inc. Secures Licensing Agreement with GEN for Crofelemer in Nine Countries

Crofelemer Jaguar Health Mytesi GEN Pharmaceutical Licensing
PRESS RELEASE

published on 03/20/2024 at 13:30, 1 year 8 months ago

GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
Jaguar Health, Inc. announces exclusive license agreement with GEN for crofelemer products in key territories, including payment of double-digit royalties. Agreement covers FDA-approved indications and potential follow-on uses

FDA-approved GEN Crofelemer Products Double-digit Royalties License Agreement
BRIEF

published on 02/23/2024 at 14:30, 1 year 9 months ago

Jaguar Health, Inc.: Update on Its Nasdaq Listing Status

Crofelemer Nasdaq Jaguar Health Clinical Trial Gastrointestinal Treatment
PRESS RELEASE

published on 02/23/2024 at 14:30, 1 year 9 months ago

Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
Jaguar Health Provides Update on Nasdaq Listing Status. Company requests appeal hearing after receiving delisting notification. Working on comprehensive analysis of Phase 3 trial for cancer therapy-related diarrhea prevention

Crofelemer Nasdaq Listing Jaguar Health Cancer Therapy Phase 3 Trial

Accesswire

Published on 12/05/2025 at 21:45, 45 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 1 hour ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 1 hour 10 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 1 hour 30 minutes ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 2 hours 5 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 14 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 17 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 3 hours 31 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 4 hours 3 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 4 hours 14 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 17:18, 5 hours 12 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 7 hours 19 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 13 hours 45 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 1 day 4 hours ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 1 day 4 hours ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE